Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP907321.RACt02IVUzn61v_1O5ZO8HLE5L3TsDAEzrq2gtdAScopk130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP907321.RACt02IVUzn61v_1O5ZO8HLE5L3TsDAEzrq2gtdAScopk130_assertion type Assertion NP907321.RACt02IVUzn61v_1O5ZO8HLE5L3TsDAEzrq2gtdAScopk130_head.
- NP907321.RACt02IVUzn61v_1O5ZO8HLE5L3TsDAEzrq2gtdAScopk130_assertion description "[If the correct targets are carefully selected for inhibition in tumors in which the targets are present (clear cell histologic features and loss of VHL expression), then results should resemble those others have observed with targeted therapy, such as the use of STI-571 (Gleevec; Novartis Pharmaceuticals, East Hanover, NJ) for treatment of chronic myelogenous leukemia and gastrointestinal stromal tumors or anti-HER2/neu (Herceptin; Genentech, South San Francisco, CA) for treatment of breast cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP907321.RACt02IVUzn61v_1O5ZO8HLE5L3TsDAEzrq2gtdAScopk130_provenance.
- NP907321.RACt02IVUzn61v_1O5ZO8HLE5L3TsDAEzrq2gtdAScopk130_assertion evidence source_evidence_literature NP907321.RACt02IVUzn61v_1O5ZO8HLE5L3TsDAEzrq2gtdAScopk130_provenance.
- NP907321.RACt02IVUzn61v_1O5ZO8HLE5L3TsDAEzrq2gtdAScopk130_assertion SIO_000772 14569078 NP907321.RACt02IVUzn61v_1O5ZO8HLE5L3TsDAEzrq2gtdAScopk130_provenance.
- NP907321.RACt02IVUzn61v_1O5ZO8HLE5L3TsDAEzrq2gtdAScopk130_assertion wasDerivedFrom befree-20140225 NP907321.RACt02IVUzn61v_1O5ZO8HLE5L3TsDAEzrq2gtdAScopk130_provenance.
- NP907321.RACt02IVUzn61v_1O5ZO8HLE5L3TsDAEzrq2gtdAScopk130_assertion wasGeneratedBy ECO_0000203 NP907321.RACt02IVUzn61v_1O5ZO8HLE5L3TsDAEzrq2gtdAScopk130_provenance.